MultiparkCoordinator & Chair of BoardProfessor Susanne Iwarsson

Assistant Coordinator & Deputy Chair of Board

Associate Professor Oskar Hansson

MultiparkStrategic research area

Advertised, applied for and evaluated by means of traditional grant

mechanisms

Transferred to the university in the annual government budget

proposition

Faculty funding – management decided by the university & faculty

Multipark2010 - 2014

110 MSEK funding for 5 years

(10, 16, 28, 28 and 28 MSEK)

3% Gothenburg University

5% Vice-chancellor, Lund University

Multipark strategy

MISSION

Goal & AimsThe principal goal is to create a program that improves body function and structure, as well as activity and participation, among PD patients. In order to reach this goal, we aim to: •Perform the first transplantation trial using stem cells •Perform clinical trials using gene-transfer based therapy •Perform clinical trials using small molecule based neuro-protective agents•Implement accurate tools for estimation of the outcome of these trials (e.g. wet biomarkers, improved rating-scales and bio-imaging)•Test the effects of evidence-based clinical interventions

Multipark focusMultipark focus

Board Executive group

Working groups

BoardChair: Susanne Iwarsson*Deputy Chair: Oskar Hansson* Faculty management representative: Ingemar Carlstedt (?)Anders BjörklundElisabet LondosCecilia Lundberg*Per Odin*Roger Olsson*Jens SchouenborgPhD student representative: Hjalmar BjartmarzPhD student representative: Zuzanna Kurowska

* Executive Group

Education & InnovationDirector of Studies:

Associate professor Helena Jernström

Innovation Group:Thomas Laurell, Roger Olsson, Tadeusz

Wieloch

Infrastructure

Done so far

•Grant manager, information officer, research & clinical administrators

•Director of Studies, 30%

•Infrastructure investments (two major equipment, plus technical & statistics resources)

•Travel grants

•Six 3rd year post-docs

Done so far• Adjunct professor Roger Olsson & co-worker =

Drug Discovery Node

• Professorship in Chemical Biology and Drug Discovery; one applicant under review

• Health Sciences Node established (postdoc, guest researchers, PhD students, facilities)

• Professor Jan Lexell

• Professor Gunnar Gouras & co-worker

• Three junior group leaders with start-up

packages (T. Björklund, L. Roybon, M. Svanberg)

Done so far•Clinical Sciences Node coming

•Visiting professor Paola Piccini

•Clinical Researcher, R. Smith – visiting Hammersmith Hospital, London

•Professorship in Clinical Neuroscience ratified by Faculty Board

•Four 50% clinical research positions under review (16 applicants)

Economic Results

2012 2013 2014 2015 2016 2017

Management+joint activities Infrastructure (evaluation 2013)FoAss Start-up Packages FoAssGraduate School Profs Start-up Packages ProfPhD students Clinical ResearchersPostdocsOther activities (i.e. innovation)TOTAL costs (MSEK)

Available (MSEK) 15.40 17.97 18.34 1.5

28.5 11.75

9.19 8.81

2012 and on•Communication & active engagement

•Infrastructure and innovation

•Experimental Sciences Node – current standing & future development

•Health Sciences, Clinical & Drug Discovery Nodes – development intensified

•Strategic development, aiming for 2015 and onwards